Effectiveness and safety of the bevacizumab and erlotinib combination <i>versus</i> erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis.

Front Oncol · 2023 · PMC10846309 · PMID 38322283

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

A highly significant heterogeneity was found among the studies ( I 2 = 82%, p < 0.0001) ( Figure 5 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.